Caricamento...
Relapsed or primary refractory AML: moving past MEC and FLAG-ida
Treatment of relapsed and refractory acute myeloid leukemia (AML) is still very challenging, with poor response rates and low chance for cure. This is especially true when treating patients who are elderly, have multiple comorbidities, or who are too unfit for traditional salvage chemotherapy regime...
Salvato in:
| Pubblicato in: | Curr Opin Hematol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Lippincott Williams And Wilkins
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7015186/ https://ncbi.nlm.nih.gov/pubmed/31904664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000561 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|